PAH pathogenesis involves multiple pathways, including mutations in the bone morphogenetic protein receptor type II (BMPR2), nitric oxide (NO) metabolism, and dysregulation of the renin–angiotensin system (RAS) [1,9,10,11,12,13]. Here, BMPR2 is linked to pulmonary arterial hypertension.